Boston Scientific Receives CE Mark for TAXUS® Liberte(TM) Long Stent
Longest drug-eluting stent approved for the management of patients with clinically challenging coronary artery disease
NATICK, Mass., and BARCELONA, Spain, May 24 /- Boston Scientific Corporation (NYSE:BSX) today announced that it has received CE Mark for its TAXUS® Liberte(TM) Long paclitaxel-eluting coronary stent system, allowing doctors to treat longer coronary artery lesions with a single stent. TAXUS Liberte Long is the longest available drug-eluting stent.
TAXUS Liberte Long is a specialty stent designed for more efficient stenting of long lesions (>32mm). Until now, patients with longer coronary lesions have required two or more overlapping stents to cover the lesion, increasing procedure time and cost. In the ARRIVE 1 and 2 registries (n=10,376 lesions), 10 percent of lesions required overlapping stents. The TAXUS Liberte Long stent allows doctors to reduce the number of stents that they use, thereby simplifying the procedure.
"Long lesions can now be treated with one TAXUS Liberte stent instead of two," said Jeff Goodman, President of Boston Scientific International. "The range of TAXUS Liberte stent sizes now available addresses the complexity of coronary artery disease and allows clinicians to choose the best stent for each patient."
The TAXUS Liberte Long stent combines a 38mm length with four diameters (2.75, 3.0, 3.5, and 4.0mm) and offers the flexibility and conformability of the TAXUS Liberte stent for the management of long lesions in a range of artery sizes. The TAXUS Liberte Long stent is CE Marked for all of the same indications as the TAXUS Liberte stent system and can be used to treat de novo lesions as well as restenotic lesions, total occlusions, and acute myocardial infarction*. The TAXUS Liberte stent system is now CE marked and available outside the United States in 58 sizes in diameters from 2.25mm to 5.0mm and lengths from 8mm to 38mm.
The TAXUS Liberte stent is currently the market-leading drug-eluting coronary stent system outside the U.S. and the first drug-eluting stent to incorporate a next-generation stent platform. The Liberte stent features the Veriflex(TM) stent design, an extremely flexible cell geometry with thin struts and uniform strut distribution. This new platform has been designed to offer improved deliverability and conformability in challenging anatomy.
The TAXUS Liberte stent and the TAXUS Liberte Long stent are not available for sale in the United States.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Source: Boston Scientific Corporation
CONTACT: Paul Donovan, Media Relations, +1-508-650-8541 office,
+1-508-667-5165 mobile, or Dan Brennan, Investor Relations,
++1-508-650-8538
office, +1-617-459-2703 mobile, both of Boston Scientific Corporation
Web site: www.bostonscientific.com/
